Drugs / HR071603
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04108234 | Oct 2019 → Jun 2021 | depressive disorder | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05414422 | Feb → Nov 2022 | — | Perception Neuroscience | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-03-16 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Perception Neuroscience Announce Collaboration on Development of PCN-101 (R-ketamine) in Japan for Treatment of Depressive Disorders otsuka.co.jp ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR071603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04108234 ↗ |
| Known as | PCN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05414422 ↗ |
| Route | Intranasal | “HR071603 monotherapy ,nasal spray” NCT04108234 ↗ |